Insulin Resistance Is Associated With Heart Failure With Recovered Ejection Fraction in Patients Without Diabetes

Insulin Resistance Is Associated With Heart Failure With Recovered Ejection Fraction in Patients Without Diabetes

Background Because of advances in medical treatments, a substantial proportion of patients with heart failure (HF) have experienced recovery of ejection fraction (EF), termed HF with recovered EF (HFrecEF). Insulin resistance (IR) is prevalent in HF and tightly related with prognosis. This study inv...

Full description

Bibliographic Details
Main Authors:	Chen Die Yang, Wen Qi Pan, Shuo Feng, Jin Wei Quan, Jia Wei Chen, Xin Yi Shu, Muladili Aihemaiti, Feng Hua Ding, Wei Feng Shen, Lin Lu, Rui Yan Zhang, Xiao Qun Wang
Format:	Article
Language:	English
Published:	Wiley 2022-10-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:	heart failure with recovered ejection fraction heart failure with reduced ejection fraction HOMA2‐IR insulin resistance
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.122.026184

Similar Items

Incidence, determinants, and outcomes of recovered left ventricular ejection fraction (LVEF) in patients with non-ischemic systolic heart failure; a hospital-based cohort study
by: Prakash Chand Negi, et al.
Published: (2023-03-01)

Long-term glycemic variability predicts compromised development of heart failure with improved ejection fraction: a cohort study
by: Chen Die Yang, et al.
Published: (2023-09-01)

Diabetic microvascular complications predicts non‐heart failure with reduced ejection fraction in type 2 diabetes
by: Mayu Tochiya, et al.
Published: (2023-04-01)

Reverse Atrial Remodeling in Heart Failure With Recovered Ejection Fraction
by: Yuxi Sun, et al.
Published: (2023-01-01)

Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides
by: Kaiyuan Zhu, et al.
Published: (2021-07-01)

Epicardial adipose tissue volume and density are associated with heart failure with improved ejection fraction
by: Chen Die Yang, et al.
Published: (2024-08-01)

Heart failure with mid‐range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines
by: Luca Branca, et al.
Published: (2020-04-01)

Association of Depression and Anxiety with Cardiac Structural and Functional Characteristics in Heart Failure with Reduced and Mildly Reduced Ejection Fraction
by: Timea Magdolna Szabo, et al.
Published: (2023-03-01)

Prediabetes and insulin resistance in a population of patients with heart failure and reduced or preserved ejection fraction but without diabetes, overweight or hypertension
by: Tran Kim Son, et al.
Published: (2022-05-01)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
by: Tin‐Kwang Lin, et al.
Published: (2019-06-01)

Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis
by: Chao Ma, et al.

Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction
by: Chiara Borrelli, et al.
Published: (2019-09-01)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
by: Lars H. Lund, et al.
Published: (2022-02-01)

Characteristics, outcomes and the necessity of continued guideline-directed medical therapy in patients with heart failure with improved ejection fraction
by: Qin-Fen Chen, et al.
Published: (2025-12-01)

Clinical predictors of improvement in left ventricular ejection fraction in U.S. veterans with heart failure
by: Shriram Nallamshetty, et al.
Published: (2022-07-01)

Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
by: Pushpraj Patel, et al.
Published: (2024-12-01)

Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction
by: Federico Ferro, et al.
Published: (2022-07-01)

Association of ambient temperature and acute heart failure with preserved and reduced ejection fraction
by: Takahiro Jimba, et al.
Published: (2022-10-01)

Left Ventricular Ejection Fraction in Heart Failure: Crazy, Stupid Love—and Maybe, Redemption
by: Milton Packer
Published: (2024-04-01)

Prevalence and Long‐Term Survival After Coronary Artery Bypass Grafting in Women and Men With Heart Failure and Preserved Versus Reduced Ejection Fraction
by: Louise Y. Sun, et al.
Published: (2018-06-01)

Interpretation of the Essential Updates in 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
by: Yifang GUO
Published: (2022-06-01)

Effect of aggressive diuresis in acute heart failure with reduced and preserved ejection fraction
by: Xin He, et al.
Published: (2021-08-01)

Sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: A review
by: Igor V. Zhirov, et al.
Published: (2023-11-01)

Correlation of β-adrenergic reactivity of erythrocyte membranes with clinical characteristics of patients with coronary artery disease and HF with preserved and reduced ejection fraction
by: E. F. Muslimova, et al.
Published: (2025-01-01)

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction
by: Luigi Falco, et al.
Published: (2023-09-01)

Five‐year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort
by: Shiqun Chen, et al.
Published: (2022-08-01)

Cardiac reverse remodelling and health status in patients with chronic heart failure
by: Kaiming Wang, et al.
Published: (2021-08-01)

Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction
by: Liam Gaziano, et al.
Published: (2021-12-01)

New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration
by: I. V. Gribkova
Published: (2024-03-01)

IL‐6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction
by: Martin Berger, et al.
Published: (2024-12-01)

Metabolomics and a Breath Sensor Identify Acetone as a Biomarker for Heart Failure
by: Patrick A. Gladding, et al.
Published: (2022-12-01)

Differences in blood pressure riser pattern in patients with acute heart failure with reduced mid‐range and preserved ejection fraction
by: Tomoya Ueda, et al.
Published: (2019-10-01)

Association of insulin use with LV remodeling and clinical outcomes in diabetic patients with heart failure and reduced ejection fraction: assessed by cardiac MRI
by: Ke Shi, et al.
Published: (2023-08-01)

Plasma levels of free fatty acid differ in patients with left ventricular preserved, mid-range, and reduced ejection fraction
by: Ning Zhu, et al.
Published: (2018-05-01)

Predictors and Prognostic Value of Worsening Renal Function During Admission in HFpEF Versus HFrEF: Data From the KorAHF (Korean Acute Heart Failure) Registry
by: Jeehoon Kang, et al.
Published: (2018-03-01)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
by: Yi Tang, et al.
Published: (2022-10-01)

Impact of diastolic dysfunction on outcome in heart failure patients with mid‐range or reduced ejection fraction
by: Dan Liu, et al.
Published: (2021-08-01)

Baseline Longitudinal Strain Predicts Recovery of Left Ventricular Ejection Fraction in Hospitalized Patients With Nonischemic Cardiomyopathy
by: Stanley A. Swat, et al.
Published: (2018-10-01)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
by: Hao Z, et al.
Published: (2022-07-01)

Combination therapy of midodrine and droxidopa for refractory hypotension in heart failure with preserved ejection fraction per a pharmacist’s proposal: a case report
by: Yuki Asai, et al.
Published: (2021-03-01)